মূল্য
দামগুলো আনুমানিক MRP এবং ফার্মেসিভেদে ভিন্ন হতে পারে। সর্বশেষ নথিভুক্ত দামের সাথে তুলনা করে ট্রেন্ড দেখানো হয়।
সব দামের পরিবর্তন →G-Thiazide T
Rx50 mg+25 mg • ট্যাবলেট
ইঙ্গিত ও ব্যবহার
G-Thiazide T এর জন্য নির্দেশিত:
ডোজ নির্দেশিকা
শুধুমাত্র নির্দেশিকা তথ্য
প্রদর্শিত ডোজগুলি সরকারি উৎসের সাধারণ নির্দেশিকা। ব্যক্তিগতকৃত ডোজের জন্য সর্বদা আপনার ডাক্তার বা ফার্মাসিস্টের পরামর্শ নিন।
প্রাপ্তবয়স্ক:
Dosage The usual dose is one or two capsules given once daily, with appropriate monitoring of serum potassium and of the clinical effect.
পার্শ্বপ্রতিক্রিয়া
Hypersensitivity: Anaphylaxis, rash, urticaria, subacute cutaneous lupus erythematosus-like reactions, photosensitivity.Cardiovascular: Arrhythmia, postural hypotension.Metabolic: Diabetes mellitus, hyperkalemia, hypokalemia, hyponatremia, acidosis, hypercalcemia, hyperglycemia, glycosuria, hyperuricemia, hypochloremia.Gastrointestinal: Jaundice and/or liver enzyme abnormalities, pancreatitis, nausea and vomiting, diarrhea, constipation, abdominal pain.Renal: Acute renal failure (one case of irreversible renal failure has been reported), interstitial nephritis, renal stones composed primarily of triamterene, elevated BUN, and serum creatinine, abnormal urinary sediment.Hematologic: Leukopenia, thrombocytopenia and purpura, megaloblastic anemia.Musculoskeletal: Muscle cramps.Central Nervous System: Weakness, fatigue, dizziness, headache, dry mouth.Miscellaneous: Impotence, sialadenitis.Central Nervous System: Paresthesias, vertigo.Ophthalmic: Xanthopsia, transient blurred vision.Respiratory: Allergic pneumonitis, pulmonary edema, respiratory distress.
সতর্কতা ও নিষেধাজ্ঞা
সতর্কতা ও সাবধানতা
Diabetes: Caution should be exercised when administering Dyazide to patients with diabetes, since thiazides may cause hyperglycemia, glycosuria, and alter insulin requirements in diabetes. Also, diabetes mellitus may become manifest during thiazide administration. Impaired Hepatic Function: Thiazides should be used with caution in patients with impaired hepatic function. They can precipitate hepatic coma in patients with severe liver disease. Potassium depletion induced by the thiazide may be important in this connection. Administer Dyazide cautiously and be alert for such early signs of impending coma as confusion, drowsiness, and tremor; if mental confusion increases discontinue Dyazide for a few days. Attention must be given to other factors that may precipitate hepatic coma, such as blood in the gastrointestinal tract or preexisting potassium depletion.Hypokalemia: Hypokalemia is uncommon with Dyazide; but, should it develop, corrective measures should be taken such as potassium supplementation or increased intake of potassium-rich foods. Institute such measures cautiously with frequent determinations of serum potassium levels, especially in patients receiving digitalis or with a history of cardiac arrhythmias. If serious hypokalemia (serum potassium less than 3.0 mEq/L) is demonstrated by repeat serum potassium determinations, Dyazide should be discontinued and potassium chloride supplementation initiated. Less serious hypokalemia should be evaluated with regard to other coexisting conditions and treated accordingly.Electrolyte Imbalance: Electrolyte imbalance, often encountered in such conditions as heart failure, renal disease or cirrhosis of the liver, may also be aggravated by diuretics and should be considered during therapy with Dyazide when using high doses for prolonged periods or in patients on a salt-restricted diet. Serum determinations of electrolytes should be performed, and are particularly important if the patient is vomiting excessively or receiving fluids parenterally. Possible fluid and electrolyte imbalance may be indicated by such warning signs as: dry mouth, thirst, weakness, lethargy, drowsiness, restlessness, muscle pain or cramps, muscular fatigue, hypotension, oliguria, tachycardia, and gastrointestinal symptoms.
নিষেধাজ্ঞা
Antikaliuretic Therapy and Potassium Supplementation: Dyazide should not be given to patients receiving other potassium-sparing agents such as spironolactone, amiloride, or other formulations containing triamterene. Concomitant potassium-containing salt substitutes should also not be used. Potassium supplementation should not be used with Dyazide except in severe cases of hypokalemia. Such concomitant therapy can be associated with rapid increases in serum potassium levels. If potassium supplementation is used, careful monitoring of the serum potassium level is necessary.Impaired Renal Function: Dyazide is contraindicated in patients with anuria, acute and chronic renal insufficiency or significant renal impairment.Hypersensitivity: Hypersensitivity to either drug in the preparation or to other sulfonamidederived drugs is a contraindication.Hyperkalemia: Dyazide should not be used in patients with preexisting elevated serum potassium.